



2024

FINANCIAL STATEMENTS BULLETIN

January-December 2024

modulight

Strong order intake and cost reductions improved cash flow despite increased R&D investments

The figures in brackets refer to the corresponding period of the previous year. This financial statement bulletin is unaudited.

Highlights in October–December 2024

- ❑ The orderbook increased by EUR 2,970 thousand and increased for the fourth consecutive quarter.
- ❑ The operating cash flow was EUR 0.8 million (-1.8 million), improving by +145%.
- ❑ Net sales were EUR 1,431 (1,019) thousand.
- ❑ EBITDA was EUR -1,023 (-2,992) thousand.
- ❑ EBITDA margin was -71.5 (-293.6) % of net sales.
- ❑ Operating profit (EBIT) was EUR -2,204 (-5,060) thousand.
- ❑ Operating profit (EBIT) was EUR -154.0 (-496.5) % of net sales.
- ❑ Earnings per share were EUR -0.02 (-0.12).

Highlights in 2024

- ❑ PPT's business developed rapidly, especially in the last quarter of the year, and the number of hospitals using the company's product increased to 47 at the end of the year.
- ❑ The total number of product development projects was 30 (28) at the end of the year.
- ❑ Net sales were EUR 4,095 (4,025) thousand.
- ❑ EBITDA was EUR -4,836 (-8,539) thousand.
- ❑ EBITDA margin was -118.1 (-212.1) % of net sales.
- ❑ Operating result (EBIT) was EUR -8,337 (-12,132) thousand.
- ❑ Operating result (EBIT) margin was -203.6 (-301.4) % of net sales.
- ❑ Earnings per share were EUR -0.15 (-0.28).
- ❑ The company's Board of Directors proposes that no dividend be paid for the financial year 2024.

Key figures

Group EUR 1,000 unless otherwise noted	10- 12/2024	10-12/2023	7-12/2024	7-12/2023	1-12/2024	1-12/2023 ¹⁾
Revenue	1,431	1,019	2,071	1,425	4,095	4,025
EBITDA	-1,023	-2,992	-2,301	-5,529	-4,836	-8,539
EBITDA-%	-71.5 %	-293.6 %	-111.1 %	-388.0 %	-118.1 %	-212.1 %
Operating result (EBIT)	-2,204	-5,060	-4,312	-8,134	-8,337	-12,132
Operating result (EBIT) -%	-154.0 %	-496.5 %	-208.2 %	-570.8 %	-203.6 %	-301.4 %
Earnings for the period	-659	-4,967	-2,627	-8,030	-6,447	-11,861
Earnings per share (EPS, EUR)	-0.02	-0.12	-0.06	-0.19	-0.15	-0.28
Acquisition of fixed and intangible assets	-1,490	-949	-2,362	-2,990	-4,900	-9,735
Free cash flow from operating activities	-2,513	-3,942	-4,663	-8,520	-9,736	-18,274
Cash and cash equivalents ²⁾	17,407	25,131	17,407	25,131	17,407	25,131
Net debt ²⁾	-12,864	-18,586	-12,864	-18,586	-12,864	-18,586
Gearing ratio ²⁾	-26.1 %	-33.4 %	-26.1 %	-33.4 %	-26.1 %	-33.4 %
Equity ratio ²⁾	87.5 %	87.1 %	87.3 %	87.1 %	87.5 %	87.1 %
Headcount (FTE) ²⁾	66	70	66	70	66	70

¹⁾ Audited

²⁾ Figure refers to the end of the review period

Outlook for 2025

Most of Modulight's customer projects are various types in the early stages of development. These projects are focused on commercializing Modulight's own products. In line with its strategy, Modulight is also transitioning from device delivery-based payments to a new treatment-session-based payment model (PPT business model). The progress of individual projects is difficult to predict, and macroeconomic and geopolitical uncertainty continue to impact market development. As a result, forecasting revenue is challenging, and Modulight does not provide guidance on revenue or profitability for the year 2025.

Seppo Orsila, CEO

The PPT business progressed rapidly with existing customers, revenue grew, and orders accumulated faster than before. Our profitability continued to improve despite increased investments in product development. Certain customer projects advanced, and we received larger pre-production orders than before. Some customer relationships also progressed faster than previously expected. Operating cash flow improved by 145% and was EUR 0.8 million (-1.8) in the fourth quarter, even though we increased product development as well as investments in sales and marketing.

Revenue in the fourth quarter was EUR 1.4 million, which was 40% more than in the corresponding period of 2023 and 123% more than in the previous quarter. Revenue development was affected by our strategic transition to the PPT business model and delays in prototype deliveries. We received more new orders than before, and in fact, this happened every quarter last year. The order backlog continued to improve throughout the year, accelerating in the second half, and this also continued at a higher level in early 2025 than last year. The projects in the order backlog are expected to generate revenue primarily in 2025. Although revenue from the PPT model is still low, the number of care facilities using our cloud-connected products has grown from about 10 at the beginning of last year to around 50 now. This growth has mostly occurred during the previous quarter. We expect growth to continue at the same or a faster pace in 2025.

Our extensive investment program has been completed, and the associated costs have decreased, which is reflected in improved profitability, even as we continue to develop our own product. Measured by EBITDA, profitability improved by 66% in the last quarter, reaching EUR -1.0 million (-3.0). Our total operating expenses have decreased by 28% since the beginning of the year compared to the reference period, despite further increasing product development as well as sales and marketing efforts. In particular, the efficiency of marketing and product development has improved. Operating cash flow improved by 145% and was EUR 0.8 million (-1.8) in the fourth quarter. The improvement in operating cash flow is also clearly visible over the first three quarters, during which it improved by 70% to EUR -1.6 million (-5.4).

The development of our business models is beginning to show in a more stable order intake, as well as in the growth rate of our install base and customer feedback. We are especially pleased with the decision of a significant U.S. managed care organization to replace all competitor devices with our PPT devices. Our role as a partner to customers has grown in terms of both the scope of our operations and the relevance of our solution. Certain customers also launched products that are partially based exclusively on our products.

Phase three clinical trials are at our focus, and certain customers want to increase the number of devices installed in the field. If these plans realize in the first half of the year, we will install a record

number of new devices, and the use of our own PPT product will increase. Device base growth is particularly seen in those indications where our profitability is above average. Positive customer feedback has been a significant factor in the growth of our product and our role as a partner in many customer relationships.

The goal of our projects is the commercialization of our own products. Our product development pipeline remained at 30 projects. These projects focus on the commercialization of our product platform across multiple indications and drugs. During this quarter, we also acquired new customers, but our collaboration with them is not yet advanced enough to report them as separate projects. We have also allocated additional resources to projects with existing customers as they progress toward commercialization. The amount of positive customer feedback has continued to grow, and we are pleased that it comes particularly from projects that are closer to commercialization.

Investments in our factory, such as production capacity and the biolaboratory, have strengthened our competitiveness. Additionally, the synergies of our platform solution are increasingly appearing as a positive competitive factor and a differentiating offering. This has concretely led, for example, to increased purchases from long-term customers. While the main focus has been on commercialization projects, we have also continued to develop our capabilities, and we are particularly proud of the development of our laser platform's micro-optics and mechanics as a competitive factor. These have recently opened up new opportunities for our products. Our broad expertise and vertical integration enable the creation of better products in a shorter time and improve the reliability of our customers' supply chains in multiple ways.

In the current global situation, our own production facility is one of our key competitive strengths. We believe this has also positively influenced the continued expansion of our customer base. We monitor changes in the global economy and geopolitics, but so far, we have not seen any reason for concern. We have interesting customers, and their number is growing, but we also have a strong cash position and the ability to respond quickly to market opportunities, for example, by increasing our product development. We will continue to focus on growth strategy initiatives such as expanding our PPT model and advancing pipeline projects to commercialize our own products. We believe that our strategic actions and strengths will contribute to our business returning to strong and profitable growth within our strategy period ending in late 2025.

Progress of the product development pipeline

The R&D pipeline, which Modulight considers the most important measure of its progress, increased by two projects from the comparison period to 30 (28), remaining at the previous quarter's level. The projects aim to commercialize the company's own products in a number of different indications and applications.


The main focus in the fourth quarter was on current pipeline projects, especially those in phase three. Examples of progress in the R&D pipeline were product announcements from certain customers based on our laser technology and positive order backlog development for several different customers.

New customers acquired during the quarter brought new opportunities for the future, but due to the early stage, these are not yet considered part of the product R&D pipeline. The company estimates that several projects in preparation have significant revenue potential.

	2020				2021				2022				2023				2024			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Total number of projects*	13	13	15	16	16	20	22	24	26	26	26	27	27	27	28	28	30	30	30	30

* To be listed here, a project needs to fulfill strict criteria related to its potential for commercial roll-out and to fit the company strategy and technological focus areas. In addition to the official projects listed in the above table, Modulight continues to work on several other initiatives, and eventually, some of these are expected to mature into projects. Classifying projects into customer groups and including or excluding them from the product development pipeline is not just the result of numerical analysis but ultimately a subjective process.

Additional information about Modulight's customers



Financial development

Revenue

October-December 2024

The Group's net sales in the last quarter of 2024 were EUR 1,431 (1,019) thousand. The change in net sales from the comparison period was EUR 412 thousand, or 40%. The development of net sales was further affected by delays in certain projects and the strategic transition towards pay-per-treatment (PPT) business model.

July-December 2024

Net sales for the second half of 2024 were EUR 2,071 (1,425) thousand. The change in net sales from the comparison period was EUR 646 thousand, or 45%. The development of net sales was further affected by delays in certain projects and the strategic transition towards pay-per-treatment (PPT) business model.

January-December 2024

The net sales for January-December 2024 were EUR 4,095 (4,025) thousand. The change in net sales from the comparison period was EUR 70 thousand, or 2%. The development of net sales was further affected by delays in certain projects and the strategic transition towards pay-per-treatment (PPT) business model.

Profitability

October-December 2024

EBITDA for the fourth quarter of 2024 was EUR -1,023 (-2,992) thousand, or -72 (-294)% of net sales. Operating profit (EBIT) was EUR -2,204 (-5,060) thousand, or -154 (-497)% of net sales. Earnings per share (EPS) was EUR -0.02 (-0.12). Profitability was improved by higher net sales than in the comparison period and a decrease in non-recurring costs related to the investment program.

July-December 2024

EBITDA for the second half of 2024 was EUR -2,301 (-5,529) thousand, or -111 (-388)% of net sales. Operating profit (EBIT) was EUR -4,312 (-8,134) thousand, or -208 (-571)% of net sales. Earnings per

share (EPS) was EUR -0.06 (-0.19). Profitability was improved by higher net sales than in the comparison period and a decrease in non-recurring costs related to the investment program.

January-December 2024

EBITDA for January-December 2024 was EUR -4,836 (-8,539) thousand, or -118 (-212)% of net sales. Operating profit (EBIT) was EUR -8,337 (-12,132) thousand, or -204 (-301)% of net sales. The result for the financial period was EUR -6,447 (-11,861) thousand and earnings per share (EPS) was EUR -0.15 (-0.28). Profitability was improved by a decrease in non-recurring costs related to the investment program.

Balance sheet, financing and investments

In 2024, investments in tangible and intangible assets amounted to EUR 4,900 (9,735) thousand. The decrease in capitalized investments was primarily due to decreased investments in tangible assets after the completion of the investment program.

Free cash flow from operating activities was EUR -9,736 (-18,274) thousand. Cash flow from operating activities was EUR -825 (-7,281) thousand.

The Group's cash and other cash equivalents on 31 December 2024 amounted to EUR 17,407 (25,131) thousand.

Net debt on 31 December 2024 was EUR -12,864 (-18,586) thousand and gearing was -26 (-33) %. The equity ratio was 88 (87) %. The return on equity in 2024 was -12 (-21) %.

Capitalized development costs were EUR 3,407 (3,349) thousand, or 27 (19) % of total operating expenses.

The total amount of trade receivables on 31 December 2024 was EUR 1,128 (915) thousand. The company considers the risks related to trade receivables to be reasonable.

Personnel and management

The number of employees (FTE) on 31 December 2024 was 66 (70), and the average number of employees in January-December 2024 was 71 (70). Personnel expenses in 2024 totaled EUR 6,231 (5,757) thousand.

On December 31, 2024, the members of Modulight Corporation's Management Team were Seppo Orsila (CEO), Anca Guina (Finance Director), Ulla Haapanen (Marketing Director), Kati Reiman (Director, SOPS & HR), Jari Sillanpää (Director, Business Development), Petteri Uusimaa (Chief Technology Officer), Kalle Palomäki (Vice President, New Product Introduction), Jukka-Pekka Alanko (Service Director) and Ville Vilokkinen (Director of Operations).

At the end of the financial year, the Board of Directors of Modulight Corporation consisted of Anne Koutonen (Chairman), Jyrki Liljeroos, Pia Kantola, Timur Kärki and Seppo Orsila.

Annual General Meeting

The Annual General Meeting of Modulight Corporation was held on May 2, 2024. The Annual General meeting adopted the company's financial statements for the financial period of January 1-December 31, 2023, and discharged the members of the Board of Directors and the CEO from liability for the financial period of January 1-December 31, 2023. Additionally, the Annual General Meeting approved the Board of Directors' proposal that the result for the year 2023 of EUR -11,773 thousand would be transferred to retained earnings and that dividends would not be paid.

The Annual General Meeting resolved that the Board of Directors consists of five members. Jyrki Liljeroos, Seppo Orsila, Pia Kantola, Timur Kärki and Anne Koutonen were re-elected as members of the Board. In the Board's inaugural meeting after the Annual General Meeting, Anne Koutonen was elected as the Chair of the Board. Anne Koutonen (Chair), Jyrki Liljeroos, Pia Kantola and Timur Kärki were elected as members of the Remuneration Committee of the Board of Directors.

The Annual General Meeting adopted the Remuneration Report for the Governing Bodies.

Authorized Public Accounting firm Moore Idman Oy was re-elected as the auditor of the company for a term that will end at the end of the next Annual General Meeting. Jari Paloniemi, Authorised Public Accountant, will be the auditor with principal responsibility.

The Annual General Meeting decided to authorize the Board of Directors to decide upon the acquisition of a maximum of 4,261,694 of the company's own shares and/or accepting the same number of the company's own shares as a pledge, in one or several tranches, by using the company's unrestricted equity. The maximum total of shares that will be acquired and/or accepted as a pledge corresponds to approximately 10% of all shares in the company as of the date of the notice to the Annual General Meeting. The shares will be repurchased otherwise than in proportion to the holdings of the shareholders via public trading arranged by Nasdaq Helsinki Oy at the market price that applies

on the date of the repurchase or at a price otherwise formed on the market. Shares can be acquired and/or accepted as a pledge e.g., in order to execute a transaction or implement share-based incentive schemes or for other purposes as decided by the Board of Directors or otherwise for the purposes of further assignment, retention or cancellation. The Board of Directors is authorized to decide on all other terms and conditions that will apply to the acquisition and/or acceptance as a pledge of the company's own shares. The authorization is valid until the closing of the next Annual General Meeting, however, no longer than June 30, 2025.

The Annual General Meeting resolved to authorize the Board of Directors to resolve on the issuance of shares as well as the issuance of option rights and other special rights entitling to shares referred to in Chapter 10, section 1 of the Finnish Limited Liability Companies Act, in one or several tranches, either against payment or without payment. The number of shares to be issued, including the shares received on the basis of the option rights and other special rights, may not exceed 4,261,694 shares, which amounts to approximately 10% of all shares in the company as of the date of the notice to the Annual General Meeting. The Board of Directors may decide to either issue new shares or to assign company shares that are held by the company. The authorization remains in force until the end of the next Annual General Meeting, however not for longer than until June 30, 2024. This authorization revokes any existing, unused authorizations to decide on a share issue and the issuance of option rights or other special rights entitling to shares.

The minutes of the Annual General Meeting can be viewed on the company's website at <https://modulight.com/agm2024/>.

Shares and shareholders

Modulight has one share class, and all shares carry equal voting rights and the right to dividends and company assets. The number of shares on 31 December 2024 was 42,616,936 (42,616,936). At the end of the financial year, the company held 130,939 (51,123) of its own shares.

The company's shares are traded on the First North Growth Market Finland marketplace maintained by Nasdaq Helsinki Ltd. During the financial year, the highest price of the share was EUR 1.55 (4.34) and the lowest price was EUR 0.70 (1.02). The weighted average price of the share during the financial year was EUR 1.04 (2.29). The closing price on 30 December 2024 was EUR 0.96 (1.17). On 31 December 2024, the Group's market capitalization was EUR 40,912 (49,862) thousand.

On 31 December 2024, Modulight Corporation had 12,080 (11,977) shareholders. The members of the Board of Directors, the CEO and the Management Team owned 41.0 (41.2) % of the shares, and the

20 largest shareholders held 75.2 (80.0) % of the total number of shares. The 20 largest shareholders of Modulight Corporation on 31 December 2024 are presented in the table below.

	Shareholder	Number of shares	% of shares and votes
1	Seppo Orsila	6,205,500	14.56 %
2	Petteri Uusimaa	6,205,500	14.56 %
3	Varma Mutual Pension Insurance Company	3,276,074	7.69 %
4	Pekka Savolainen	3,054,422	7.17 %
5	Ville Vilokkinen	3,039,750	7.13 %
6	Petri Melanen	2,173,500	5.10 %
7	Pekko Sipilä	1,630,125	3.83 %
8	Mika Saarinen	1,630,125	3.83 %
9	Mandatum Life Insurance Company	827,109	1.94 %
10	Ancuta Guina	670,320	1.57 %
11	Juha Lemmetti	553,140	1.30 %
12	Jyri Merivirta	500,000	1.17 %
13	Jyrki Liljeroos	460,950	1.08 %
14	Kalle Palomäki	414,855	0.97 %
15	Protean Funds Scandinavia	364,504	0.86 %
16	Kati Reiman	293,580	0.69 %
17	Petri Suokas with close associates	281,250	0.66 %
18	Hubert Jouve	200,737	0.47 %
19	Kaleva Mutual Insurance Company	149,957	0.35 %
20	Sp-Fund Management	133,778	0.31 %

Option programs

Modulight has offered its personnel stock option programs as part of the incentive and commitment program. The company had two option programs at the end of 2024. There was a total of 1,101,945 unused options on December 31, 2024. No new shares were subscribed with stock options during 2024.

Outstanding option programs are presented in the table below.

Option Program	Authorization given by the general meeting	Option rights granted according to authorization	Option rights not granted according to authorization	Of the options granted, exercised	Unused Options	Subscription Price EUR	Subscription Period
----------------	--	--	--	-----------------------------------	----------------	------------------------	---------------------

2021	852,758	667,021	185,737	0	667,021	6.49	Dec 31, 2023- Dec 31, 2025
2023	500,000	434,924	65,076	0	434,924	2.43	Dec 31, 2025- Dec 31, 2028

Assessment of short-term risks and uncertainties

Modulight's short-term risks and uncertainties primarily concern the company's business and industry. These risks relate, for example, to technological developments and the competitive situation, the supply chain, the availability of materials, the development of the healthcare sector and the availability of skilled labor. In addition, there are risks associated with the company's intellectual property rights, as well as with obtaining market authorizations for products. The general global political situation may affect both customers and the company and its business significantly and more than previously estimated.

The company operates in the medical and biomedical field and focuses especially on the US market. Various product and patient liability issues can be a significant risk for the company.

Increasing cybercrime can also be a significant and growing risk, especially since the company is now more widely recognized. The company may suffer malfunctions or outages in its information technology, network or communications systems and/or be subject to cyber security breaches.

The company is also exposed to credit and counterparty and risks, if its contractual parties are unable to fulfil their contractual obligations. Counterparty risk is mainly related to trade receivables and receivables related to financing instruments.

The success of Modulight's business and growth strategies also depends on the company's ability to recruit and retain skilled personnel. The availability or loss of key personnel could have a material adverse effect on Modulight's business.

Market overview and operating environment

The medical markets relevant to Modulight Corporation are particularly related to cancer treatment (oncology), ophthalmology, genetics and diagnostics. In addition to the medical market, Modulight has identified business opportunities for its technology in the markets of other high value-add applications, such as quantum computing, flow cytometry, diagnostics and digital printing.

The global oncology pharmaceutical market was USD 218 billion in 2023 and is expected to grow to USD 380 billion by 2027. Although Modulight is targeting only a portion of the global oncology market

and concentrating on the U.S. market in particular, the significant growth in the overall market also means an increase in the demand for laser-based oncology treatments and new opportunities globally. Growth in the oncology market is driven especially by a globally aging population. Age is known to be one major factor in the increase in the incidence of cancers. In 2023, as part of the transition to the PPT business model, Modulight studied the cost of cancer treatment in the United States for indications relevant or otherwise interesting to the company. The studied indications do not represent the company's entire product development pipeline. The study currently covers 10 different indications in the field of oncology. The median (weighted) cost of standard of care per patient for these indications is USD 320,000 and ranges between USD 100,000 and USD 420,000 for different indications. The company expects that using its treatment with the PPT business model and technology will not only improve the outcome of treatment and its accessibility, but also reduce the total cost of treatment. The number of patients and treatment costs for specific cancers in the United States are presented below.

Indication	Annual incidence in United States (patients)	Median cost of treatment path (USD)
Retinal cancer of the eye	2,000	100,000
Head and neck cancer	66,000	200,000
Pancreatic cancer	64,000	275,000

The ophthalmic treatment market has also continued to grow. The global market totaled USD 33 billion in 2022, and it is expected to grow to USD 54 billion by 2030. The growth of the market is supported primarily by the continuous increase in ophthalmic diseases due to the aging population and the growing R&D investments in the development of eye disease treatments.

In the fields of genetics and diagnostics, the combined market for next-generation sequencing, endoscopes and flow cytometry is estimated to grow from USD 26 billion in 2022 to USD 52 billion by the end of the decade. One of the main growth factors in the genetics and diagnostics market is the need for personalized drug therapies in the treatment of cancers. Other important drivers of growth include the need for scalable cloud-based care solutions.

The quantum computing market is just emerging. Forecasts of its growth vary significantly, but all point to significant growth in the industry in the next few years. Modulight monitors the market mainly through its customers and, in line with its strategy, aims to offer its products also for quantum computing to maximize synergy benefits.

Strategy and targets

Modulight's growth targets in the strategy period 2023–2025 are based on the following key strategic factors:

1. geographical expansion
2. extension of the offering to new indications and applications
3. new business models
4. commercial and operational excellence
5. state-of-the-art laser technology expertise

Modulight's main business targets are:

- at least three commercial roll outs of projects in the current R&D pipeline
- local operations in the U.S. and focusing on selected partnerships in Europe and Asia
- developing a pay per treatment model and other SaaS-based business models
- improving treatment efficacy and accessibility with cloud-based services
- carbon-neutral operations in 2025

Modulight implements its strategy especially through the following programs:

- sales, marketing and operations development
- cloud technology and cloud-based services development
- productizing platform devices for various indications and applications
- technology development based on the completed investment program
- development of ESG, governance and reporting

Modulight's financial target is strong annual growth and a return to strong profitability during the strategy period 2023–2025. The company's dividend policy remains unchanged.

- Growth: strong annual revenue growth
- Profitability: return to strong profitability in terms of operating margin (EBITDA-%)
- Dividend policy: all returns invested in organic and inorganic growth, and the company distributes little or no dividends

Board of Directors' proposal for the treatment of distributable funds

The distributable equity of the Group's parent company Modulight Oyj on 31 December 2024 was EUR 38,359 (46,960) thousand. The company's Board of Directors proposes to the Annual General Meeting that no dividend be distributed for the 2024 financial year.

Annual General Meeting

The Annual General Meeting is scheduled to be held on 2 May 2025. The meeting will be convened later by the Board of Directors of Modulight Corporation.

Financial reporting in 2025

In 2025, Modulight will publish the following financial reports:

- ❑ Interim report January-March 2025: 25 April 2025
- ❑ Half-year financial report January-June 2025: 22 August 2025
- ❑ Interim report January-September 2025: 24 October 2025

Tables January 1 - December 31, 2024

Accounting principles for the consolidated financial statements

The financial figures have been prepared in accordance with the Finnish Accounting Standards (FAS).

The figures in this financial statements bulletin are unaudited, unless otherwise mentioned. Full-year 2023 figures are audited.

Consolidated income statement

EUR 1,000	10-12/2024	10-12/2023	7-12/2024	7-12/2023	1-12/2024	1-12/2023
REVENUE	1,431	1,019	2,071	1,425	4,095	4,025
Change in inventory	-12	-209	-92	153	197	304
Manufacturing for own use	939	395	1,554	1,199	3,407	3,349
Other operating income		338	42	556	64	1,171
Raw materials and services						
Raw materials and consumables						
Purchases during reporting period	-81	-871	-344	-1,423	-1,312	-2,693
Change in inventory	-404	144	-263	-130	-426	-2
External services	-34	-141	-59	-100	-176	-571
Total raw materials and services	-520	-868	-665	-1,652	-1,914	-3,266
Personnel expenses						
Wages and salaries	-1,353	-1,321	-2,415	-2,351	-5,201	-4,792
Social security services						
Pension expenses	-229	-240	-410	-424	-886	-851
Other social security services	-60	-38	-81	-75	-144	-115
Total personnel expenses	-1,642	-1,599	-2,906	-2,850	-6,231	-5,757
Depreciation and amortization						
Depreciation and amortization according to plan	-1,180	-2,068	-2,010	-2,605	-3,501	-3,593
Other operating expenses	-1,219	-2,068	-2,305	-4,360	-4,453	-8,365
OPERATING PROFIT(-LOSS)	-2,204	-5,060	-4,312	-8,134	-8,337	-12,132
Financial income and expenses						
Other interest and financial income	1,626	185	1,810	220	2,099	246
Interest and financial expenses	-82	-91	-125	-115	-210	26
Total financial income and expenses	1,544	94	1,685	105	1,890	272
PROFIT (-LOSS) BEFORE APPROPRIATIONS AND TAXES	-659	-4,966	-2,627	-8,029	-6,447	-11,860
Income taxes		-1		-1		-1
PROFIT (-LOSS) FOR THE FINANCIAL PERIOD	-659	-4,967	-2,627	-8,030	-6,447	-11,861

Consolidated balance sheet

EUR 1,000	Dec 31, 2024	Dec 31, 2023
ASSETS		
Non-current assets		
Intangible assets		
Development expenditure	10,843	8,916
Intangible rights	55	
Total intangible assets	10,898	8,916
Fixed assets		
Buildings and structures	3,157	3,326
Machinery and equipment	20,960	21,266
Other fixed assets	176	285
Total fixed assets	24,294	24,877
Total non-current assets	35,192	33,793
Current assets		
Inventory		
Raw materials and consumables	1,131	1,560
Finished products	1,190	993
Total inventory	2,321	2,553
Receivables		
Short-term receivables		
Sales receivables	1,128	915
Other receivables	111	1,209
Prepayments and accrued income	137	360
Total short-term receivables	1,376	2,485
Financial securities		24,721
Cash and cash equivalents	17,407	409
Total current assets	21,104	30,169
TOTAL ASSETS	56,296	63,962

EUR 1,000	Dec 31, 2024	Dec 31, 2023
EQUITY AND LIABILITIES		
Equity		
Share capital	80	80
Reserve for invested unrestricted equity	75,308	75,317
Retained earnings	-19,659	-7,809
Earnings for the reporting period	-6,447	-11,861
Total equity	49,282	55,727
Liabilities		
Non-current liabilities		
Loans from financial institutions	2,791	4,543
Total non-current liabilities	2,791	4,543
Current liabilities		
Loans from financial institutions	1,752	2,002
Advances received	451	55
Accounts payable	659	569
Other liabilities	123	136
Accrued expenses	1,238	930
Total current liabilities	4,223	3,692
Total liabilities	7,014	8,235
TOTAL EQUITY AND LIABILITIES	56,296	63,962

Consolidated cash flow statement

EUR 1,000	10-12/2024	10-12/2023	7-12/2024	7-12/2023	1-12/2024	1-12/2023
Cash flow from operating activities						
Operating profit	-2,204	-5,060	-4,312	-8,134	-8,337	-12,132
Depreciation and amortization	1,180	2,068	2,010	2,605	3,501	3,593
Net financial expenses	1,544	94	1,685	105	1,890	272
Change in working capital, increase (-), decrease (+)	298	1,068	813	1,855	2,121	986
Taxes paid		-1		-1		-1
Cash flow from operating activities (A)	819	-1,832	197	-3,570	-825	-7,281
Cash flow from investing activities						
Investments in tangible and intangible assets	-1,600	-6,237	-2,273	-8,340	-5,009	-15,695
Advance payments	110	5,288	-89	5,350	109	5,960
Cash flow from investing activities (B)	-1,490	-949	-2,362	-2,990	-4,900	-9,735
Cash flow from financing activities						
Change in interest-bearing debts	-464	-450	-1,001	-994	-2,002	-1,739
Acquisition of own shares (-) / transfer (+)	-9		-9	-16	-9	-16
Cash flow from financing activities (C)	-474	-450	-1,010	-1,010	-2,011	-1,755
Net cash flow (A+B+C)	-1,144	-3,231	-3,175	-7,570	-7,736	-18,772
Cash at the beginning of the period	18,531	28,323	20,565	32,661	25,131	43,870
Exchange rate differences	20	39	16	40	12	33
Cash at the end of the period	17,407	25,131	17,407	25,131	17,407	25,131

Changes in equity items and distributable funds

EUR 1,000	1-12/2024	1-12/2023
Restricted equity		
Share capital January 1	80	80
Share capital increases		
Share capital December 31	80	80
Total restricted equity December 31	80	80
Unrestricted equity		
Reserve for invested unrestricted equity January 1	75,317	75,334
Increases in the reserve for invested unrestricted equity	-9	-16
Reserve for invested unrestricted equity December 31	75,308	75,317
Profit (-loss) for previous financial years January 1	-19,671	-7,843
Translation difference	12	34
Dividends distributed in the reporting period		
Profit (-loss) for previous financial years December 31	-19,659	-7,809
Profit for the reporting period	-6,447	-11,861
Unrestricted equity December 31	49,202	55,647
Total equity December 31	49,282	55,727

Calculation formulas for key figures

Key figures	Definition	Reason for the use
Growth of revenue, %	$(\text{Revenue for the period} - \text{revenue for the previous reference period}) / \text{Revenue for the previous period}$	Revenue growth is an indicator to measure the growth of the company.
EBITDA	Operating result before depreciation and amortization	EBITDA is an indicator to measure the operational performance of the company.
EBITDA, %	$\text{EBITDA} / \text{Revenue}$	Operating margin is an indicator to measure the operational performance of the company.
Operating result	Operating result as presented in the income statement	Operating result is an essential indicator for the understanding of the company's financial performance.
Operating result, %	$\text{Operating result} / \text{Revenue}$	Operating result is an essential indicator for the understanding of the company's financial performance.
Earnings per share	$\text{Earnings for the period} / \text{weighted average number of outstanding shares during the period}$	Indicator describes the distribution of operating result to individual shares.
Acquisition & scrapping on fixed and intangible assets	Acquisition & scrapping of fixed and intangible assets as presented in the statement of cash flow	Indicator produces more information on the cash flow needs for operational investments.
Free cash flow operating activities	$\text{EBITDA} - \text{Acquisitions \& scrapping of fixed and intangible assets as presented in the statement of cash flow}$	Indicator gives information of the cash flow which the company is able to generate after operational investments.
Net debt	$\text{Interest-bearing debt} - \text{Cash and cash equivalents (at the end of the period)}$	Net debt is an indicator to measure the total external debt financing of the company.
Gearing ratio	$(\text{Interest-bearing debt} + \text{Cash and cash equivalents (at the end of the period)}) / \text{Equity}$	Indicator for the management to track the company's level of equity.
Equity ratio	$\text{Equity} / \text{Total equity}$	Indicator for the proportion of the company's assets that have been financed with equity.
Return on equity, %	$100 \times \text{Earnings for the period} / \text{Adjusted average equity}$	Indicator for the company's ability to generate profits in relation to equity belonging to the owners.

For further information, please contact:

CEO: Seppo Orsila m. +358 40 830 4671

IR: Ulla Haapanen m. +358 40 830 4676

email: ir@modulight.com

Certified adviser: Sisu Partners Oy

www.modulight.com

Twitter: [@modulight](https://twitter.com/modulight)

Modulight in brief

Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company's products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight's products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland. www.modulight.com

modulight

www.modulight.com